Key facts
- It has raised $9.2M; the latest was Later Stage VC ($5.0M) in May 2025.
- Notable investors include European Innovation Council, Startupbootcamp Holding, Limburg Development and Investment Company, Brightlands Venture Partners, DutchBasecamp — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for HY2Care
- ·The full record, as it builds
Funding rounds
No funding rounds for HY2Care are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HY2Care
Manufacturer of an injectable hydrogel designed to repair cartilage defects. The company's two-component injectable and bioresorbable hydrogel are composed of a mixture of natural polymer conjugates that cross-link in a mild enzymatic reaction, enabling clinicians to treat patients with functional repair of cartilage defects in the knee.
- Sector
- Healthcare
- HQ
- Geleen, Netherlands
- Founded
- 2014
- Employees
- 12
- Website
- hy2care.com/
- Ownership
- Privately Held (backing)
HY2Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HY2Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HY2Care in its N-PORT filings yet. We sweep new filings monthly.